CompletedPhase 3

Influence of Pioglitazone for Renal Transplant Function in Diabetics

GermanyStarted 2007-07

Plain-language summary

The purpose of this study is to test whether pioglitazone is able to prevent the progression of diabetic nephropathy in kidney transplant recipients with diabetes mellitus.

Who can participate

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * kidney transplantation(\> 6 months ago) ; stable graft function * diabetes mellitus type 2 * acceptable glycemia (HbA1c \< 8%) * creatinin clearance (MDRD)\>30 ml/min 1,73m²) * proteinuria \> 30 mg/24 hr Exclusion Criteria: * type 1 diabetes * pregnant or breast feeding women * congestive heart failure (\>stage 1 NYHA) * creeping creatinin * treatment for rejection within 3 months prior to inclusion * ALT, AST \> 2.5 fold the upper limit of normal * uncontrolled hypertension * hypo- or hyperthyroidism

What they're measuring

proteinuria

Timeframe: 12 weeks

Trial details

NCT IDNCT00507494

SponsorTechnische Universität Dresden

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-09

View on ClinicalTrials.gov More Diabetes Mellitus trials